Eur Radiol:肝癌根治术后短期又出现了复发,如何在术前评估一下呢?

2021-02-25 shaosai MedSci原创

对于肝功能储备良好的HCC患者,尤其是早期HCC,根治性切除术是普遍认为的最佳治疗方式。然而,由于术后的高复发率,HCC患者的长期预后仍不令人满意。

    肝细胞肝癌(HCC)是原发性肝脏恶性肿瘤中最常见的类型,占原发性肝脏恶性肿瘤的70-90%。肝癌的治疗方式包括手术切除、肝移植、介入治疗、化疗和放疗。对于肝功能储备良好的HCC患者,尤其是早期HCC,根治性切除术是普遍认为的最佳治疗方式。然而,由于术后的高复发率,HCC患者的长期预后仍不令人满意。

    早期HCC复发定义为手术切除后2年内肝内出现新HCC病灶,而手术切除后2年以上出现新病灶则被认为是肝硬化背景下发生的多中心肝癌,与原病灶无关。肿瘤大小、包膜增强、ADC值、MRI肝胆期图像上病灶与肝脏的增强比等影像学所衍生的生物指标已在多项研究中证实可作为预测HCC的预后因素。这些影像学预测指标有助于临床上筛选适合于根治性肝细胞癌切除术的患者。

    能谱CT是最近引入的一种可以减少波束硬化伪影效应的新的扫描模式,并能准确地获得定量碘浓度(IC)测量所需的分解图像。在许多实体肿瘤如胰腺癌、非小细胞肺癌、胃癌等中,碘的浓度与肿瘤中微血管密度相关。在最近的兔肝肿瘤模型研究中也发现了这种相关性。血管生成是肿瘤生长和转移的先决条件,而已有多项研究表明,肿瘤微血管密度是预测肿瘤早期复发的重要预测因子。


    近日,发表在European Radiology杂志的一项研究表明从HCC病变的血管生成分析中提取的标准化碘浓度(NIC)与HCC患者的肿瘤微血管密度和早期复发有关,从而证实NIC可以作为手术切除后早期复发的预测因子。

  

  本项前瞻性研究纳入了71例手术切除的单发HCC患者,每位患者均在2014年11月至2016年6月期间接受了术前能谱CT检查。两名观察者分别在动脉期(AP)和门静脉期(PVP)测量NIC。评价NIC与微血管密度的关系。采用单因素和多因素logistic回归评估早期复发的独立预测因素。

    71例患者中有28例(39.4%)在2年随访中出现早期复发。在两位观察者中,NIC-AP与微血管密度呈正相关(r = 0.593和0.527)。基于多因素分析,早期肝癌复发的独立危险因素为肿瘤大小(优势比,1.200;p = 0.043)NIC-AP(优势比,2.522;p = 0.005)。两位观察者预测早期HCC复发的受试者工作特征曲线下面积分别为0.719和0.677。NIC-AP值高于最佳截断值的患者中,早期复发率明显高于低于最佳截断值的患者。

 

1 规范化碘浓度与肝细胞癌患者微血管密度的关系。(a)观察者1 (r = 0.593, p < 0.001)和(b)观察者2 (r = 0.527, p < 0.001)NIC-AP和微血管密度之间的相关性,和(c)观察者1 (r = 0.333, p = 0.004)和(d)观察者2 (r = 0.213, p = 0.074)NIC-PVP和微血管密度之间的相关性。如图所示,NIC-AP与微血管密度呈正相关(r = 0.593和0.527)。

2 Kaplan-Meier曲线分析。NIC-AP值高于最佳截断值的患者中,早期复发率明显高于低于最佳截断值的患者。

    能谱CT动脉期的标准化碘浓度反映了肿瘤相关的血管生成,是肝细胞癌早期复发的潜在预测生物标志物。


原始出处:

Ningbin Luo,Wenzhu Li,Jisheng Xie,et al. Preoperative normalized iodine concentration derived from spectral CT is correlated with early recurrence of hepatocellular carcinoma after curative resection. DOI:10.1007/s00330-020-07330-6

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1399750, encodeId=359f1399e5064, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490433, encodeId=cc601490433b0, content=<a href='/topic/show?id=52476102342' target=_blank style='color:#2F92EE;'>#术前评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61023, encryptionId=52476102342, topicName=术前评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8afa8737210, createdName=ay2003fy, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586209, encodeId=841915862091d, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040359, encodeId=09cb1040359ed, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Feb 25 21:52:48 CST 2021, time=2021-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1399750, encodeId=359f1399e5064, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490433, encodeId=cc601490433b0, content=<a href='/topic/show?id=52476102342' target=_blank style='color:#2F92EE;'>#术前评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61023, encryptionId=52476102342, topicName=术前评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8afa8737210, createdName=ay2003fy, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586209, encodeId=841915862091d, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040359, encodeId=09cb1040359ed, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Feb 25 21:52:48 CST 2021, time=2021-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1399750, encodeId=359f1399e5064, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490433, encodeId=cc601490433b0, content=<a href='/topic/show?id=52476102342' target=_blank style='color:#2F92EE;'>#术前评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61023, encryptionId=52476102342, topicName=术前评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8afa8737210, createdName=ay2003fy, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586209, encodeId=841915862091d, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040359, encodeId=09cb1040359ed, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Feb 25 21:52:48 CST 2021, time=2021-02-25, status=1, ipAttribution=)]
    2021-02-27 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1399750, encodeId=359f1399e5064, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490433, encodeId=cc601490433b0, content=<a href='/topic/show?id=52476102342' target=_blank style='color:#2F92EE;'>#术前评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61023, encryptionId=52476102342, topicName=术前评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8afa8737210, createdName=ay2003fy, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586209, encodeId=841915862091d, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Feb 27 09:52:48 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040359, encodeId=09cb1040359ed, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Feb 25 21:52:48 CST 2021, time=2021-02-25, status=1, ipAttribution=)]
    2021-02-25 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

相关资讯

腹腔镜胃癌根治术的优势有哪些?

在我国胃癌的发病率很高,然而胃癌的早期诊断率比较低,给胃癌的治疗带来不便。那么您了解胃癌吗? 胃癌的诱发因素众多,如地域环境、饮食生活方式(长期食用盐腌、熏烤食品)、幽门螺杆菌感染、慢性疾患及遗传等因素。胃癌按照肿瘤侵犯程度的不同可分为早期胃癌和进展期胃癌。

一例AIDS患者食管癌根治术中气管撕裂的麻醉管理体会

患者,男,58岁,身高171 cm,体重64kg。因“吞咽困难2月余,确诊食管癌3d”入院。患者2个多月前无明显诱因下开始出现进食哽咽,进食后约2秒后有异物感,伴胸骨后不适感,并逐渐出现吞咽困难症状,当时未重视。1个月前,无法进食较大块食物,伴恶心,并出现呕吐进食物品,能进半流质及流质饮食,但较硬食物难以下咽。无反酸、嗳气,无胸骨后灼烧痛,无发热、恶寒,无腹胀、腹泻,食量减少至原来的1/2。在外院

病例:特瑞普利单抗联合化疗新辅助治疗获PR,初始手术困难的食管鳞癌患者成功施行根治术

免疫治疗在食管癌中进展迅速,已在晚期食管癌患者的二线及以上治疗中表现出较化疗更优的生存结果。其在食管癌一线治疗中的研究也有多项在进行中。不仅如此,鉴于免疫治疗的治疗潜力,其与化疗、化放疗联合用于可切除食管癌新辅助治疗的研究也取得了初步成果,为局部晚期的患者带来了获益可能。本文介绍的这例食管癌患者,初始手术切除有困难,经PD-1单抗特瑞普利单抗联合化疗新辅助治疗后,原发灶明显缩小,得以成功实施根治性

JAMA:局部前列腺癌治疗的3种方法哪个更好?

了解目前局部前列腺癌治疗方法的不良影响可以为共同决策提供相关信息。近期,一项发表在权威杂志JAMA上的研究旨在比较与根治性前列腺切除术相比,外部束放射治疗(EBRT)和主动监测相关的功能结果和不良反应。此项研究是前瞻性、基于人群的队列研究,收集了2011-2012年诊断为临床cT1-2期的2550名男性(≤80岁)局限性前列腺癌,且前列腺特异性抗原水平低于50 ng / mL,并在6个月内诊断的患

SCI REP:前列腺癌根治术后盆底重建改选什么方法?

由此可见,接受根治性前列腺切除术的患者并且采用后路重建治疗尿失禁出现最少。采用前壁悬吊、前路重建联合后路重建治疗和前壁悬吊联合后路重建治疗在术后没有观察到明显的益处。

Lung Cancer:经VATS根治妊娠肺癌

妊娠合并肺癌少见,发生率接近1/1000。最常报道的妊娠合并恶性肿瘤是乳腺癌、宫颈癌、恶性黑色素瘤、淋巴瘤和白血病,很少有报道妊娠合并肺癌。韩国Jeong-Won Kim教授等报道了一例女性患者,在孕24周时发现右下肺叶肿块且体积不断增大,该文发表在2014年8月的肺癌杂志(Lung Cancer)。 CT示右下肺叶一直径约7.5cm的肿块。在评估了患者获益和胎儿的风险之后,作者采取VATS